Cell Therapy for Chronic TBI
Open Access
- 23 February 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 96 (8), e1202-e1214
- https://doi.org/10.1212/wnl.0000000000011450
Abstract
Objective To determine whether chronic motor deficits secondary to traumatic brain injury (TBI) can be improved by implantation of allogeneic modified bone marrow–derived mesenchymal stromal/stem cells (SB623). Methods This 6-month interim analysis of the 1-year double-blind, randomized, surgical sham–controlled, phase 2 Stem Cell Therapy for Traumatic Brain Injury (STEMTRA) trial (NCT02416492) evaluated safety and efficacy of the stereotactic intracranial implantation of SB623 in patients with stable chronic motor deficits secondary to TBI. Patients in this multicenter trial (n = 63) underwent randomization in a 1:1:1:1 ratio to 2.5 × 106, 5.0 × 106, or 10 × 106 SB623 cells or control. Safety was assessed in patients who underwent surgery (n = 61), and efficacy was assessed in the modified intent-to-treat population of randomized patients who underwent surgery (n = 61; SB623 = 46, control = 15). Results The primary efficacy endpoint of significant improvement from baseline of Fugl-Meyer Motor Scale score at 6 months for SB623-treated patients was achieved. SB623-treated patients improved by (least square [LS] mean) 8.3 (standard error 1.4) vs 2.3 (standard error 2.5) for control at 6 months, the LS mean difference was 6.0 (95% confidence interval 0.3–11.8, p = 0.040). Secondary efficacy endpoints improved from baseline but were not statistically significant vs control at 6 months. There were no dose-limiting toxicities or deaths, and 100% of SB623-treated patients experienced treatment-emergent adverse events vs 93.3% of control patients (p = 0.25). Conclusions SB623 cell implantation appeared to be safe and well tolerated, and patients implanted with SB623 experienced significant improvement from baseline motor status at 6 months compared to controls. ClinicalTrials.gov Identifier: NCT02416492. Classification of Evidence This study provides Class I evidence that implantation of SB623 was well tolerated and associated with improvement in motor status.This publication has 28 references indexed in Scilit:
- Stem Cell Recruitment of Newly Formed Host Cells via a Successful Seduction? Filling the Gap between Neurogenic Niche and Injured Brain SitePLOS ONE, 2013
- Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injuryBrain Research, 2013
- Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest, 2012
- Fugl-Meyer Assessment of Sensorimotor Function After StrokeStroke, 2011
- Notch-Induced Rat and Human Bone Marrow Stromal Cell Grafts Reduce Ischemic Cell Loss and Ameliorate Behavioral Deficits in Chronic Stroke AnimalsStem Cells and Development, 2009
- Extracellular matrix produced by bone marrow stromal cells and by their derivative, SB623 cells, supports neural cell growthJournal of Neuroscience Research, 2009
- Incidence of Long-term Disability Following Traumatic Brain Injury Hospitalization, United States, 2003Journal of Head Trauma Rehabilitation, 2008
- Motor impairment after severe traumatic brain injury: A longitudinal multicenter studyJournal of Rehabilitation Research and Development, 2007
- A Standardized Approach to Performing the Action Research Arm TestNeurorehabilitation and Neural Repair, 2007
- A performance test for assessment of upper limb function in physical rehabilitation treatment and researchInternational Journal of Rehabilitation Research, 1981